AU2001280812A1 - Gsk3 polypeptides - Google Patents

Gsk3 polypeptides

Info

Publication number
AU2001280812A1
AU2001280812A1 AU2001280812A AU8081201A AU2001280812A1 AU 2001280812 A1 AU2001280812 A1 AU 2001280812A1 AU 2001280812 A AU2001280812 A AU 2001280812A AU 8081201 A AU8081201 A AU 8081201A AU 2001280812 A1 AU2001280812 A1 AU 2001280812A1
Authority
AU
Australia
Prior art keywords
gsk3
polypeptides
amino acid
substituted amino
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280812A
Inventor
Maria Calderon-Cacia
Doris G. Coit
Eric Y. Fang
John A Hall
Stephen D. Harrison
Angelica Medina-Selby
Steven H. Nguyen
Ziyang Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001280812A1 publication Critical patent/AU2001280812A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)

Abstract

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
AU2001280812A 2000-07-27 2001-07-25 Gsk3 polypeptides Abandoned AU2001280812A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22124200P 2000-07-27 2000-07-27
US60/221,242 2000-07-27
PCT/US2001/023539 WO2002010357A2 (en) 2000-07-27 2001-07-25 Gsk3 polypeptides

Publications (1)

Publication Number Publication Date
AU2001280812A1 true AU2001280812A1 (en) 2002-02-13

Family

ID=22826991

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280812A Abandoned AU2001280812A1 (en) 2000-07-27 2001-07-25 Gsk3 polypeptides

Country Status (10)

Country Link
US (6) US6465231B2 (en)
EP (2) EP1319064B1 (en)
JP (1) JP2004504838A (en)
CN (1) CN1276974C (en)
AT (1) ATE450604T1 (en)
AU (1) AU2001280812A1 (en)
DE (2) DE60131550T2 (en)
ES (1) ES2295191T3 (en)
PT (2) PT1319064E (en)
WO (1) WO2002010357A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292906B2 (en) * 2000-09-19 2007-08-16 Novartis Vaccines And Diagnostics, Inc. Characterization of the GSK-3beta protein and methods of use thereof
JP2005532265A (en) * 2002-02-11 2005-10-27 カイロン コーポレイション Method for crystallizing human GSK3 and its novel crystal structure
WO2005083111A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 alpha (gsk3a)
US20060127388A1 (en) * 2004-12-10 2006-06-15 Wyeth Variants of glycogen synthase kinase 3 and uses thereof
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
JPWO2006073202A1 (en) * 2005-01-04 2008-08-07 国立大学法人金沢大学 Cancer suppression based on GSK3β inhibitory effect and method for evaluating anticancer agent
EA016397B1 (en) * 2005-06-20 2012-04-30 Декоуд Дженетикс Ехф. Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus
JP2009504657A (en) * 2005-08-09 2009-02-05 メタプロテオミクス，エルエルシー Protein kinase regulation by hops and acacia products
JP5933544B2 (en) 2010-07-26 2016-06-08 バイオマトリカ， インコーポレーテッド Compositions for stabilizing blood DNA, RNA and proteins and other biological samples shipped and stored at ambient temperature
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2934572A4 (en) 2012-12-20 2016-11-23 Biomatrica Inc Formulations and methods for stabilizing pcr reagents
CA2915250A1 (en) 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3656215B1 (en) 2014-06-10 2021-08-04 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
AU2016368265B2 (en) 2015-12-08 2021-10-28 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
CN117384983B (en) * 2023-12-07 2024-02-23 中国中医科学院中药研究所 Preparation method of GSK-3 alpha inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591872A (en) * 1993-08-09 1997-01-07 The University Of Iowa Research Foundation Autoinducer molecule
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5693496A (en) * 1994-06-20 1997-12-02 Merck & Co., Inc. DNA encoding the mouse and human PH30 beta chain protein
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
CA2329694A1 (en) * 1998-05-28 1999-12-02 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6057218A (en) * 1999-05-07 2000-05-02 Vanguard International Semiconductor Corporation Method for simultaneously manufacturing poly gate and polycide gate

Also Published As

Publication number Publication date
US20060088932A1 (en) 2006-04-27
DE60131550D1 (en) 2008-01-03
CN1468302A (en) 2004-01-14
WO2002010357A2 (en) 2002-02-07
US7361484B2 (en) 2008-04-22
ES2295191T3 (en) 2008-04-16
US7195886B2 (en) 2007-03-27
EP1914305A1 (en) 2008-04-23
DE60131550T2 (en) 2008-10-23
US6716624B2 (en) 2004-04-06
US20030077798A1 (en) 2003-04-24
EP1319064A2 (en) 2003-06-18
EP1319064B1 (en) 2007-11-21
US20070249004A1 (en) 2007-10-25
US20020082408A1 (en) 2002-06-27
DE60140707D1 (en) 2010-01-14
EP1914305B1 (en) 2009-12-02
US7135321B2 (en) 2006-11-14
US6465231B2 (en) 2002-10-15
CN1276974C (en) 2006-09-27
JP2004504838A (en) 2004-02-19
ATE450604T1 (en) 2009-12-15
US20080182313A1 (en) 2008-07-31
WO2002010357A3 (en) 2003-04-03
US20050048511A1 (en) 2005-03-03
PT1914305E (en) 2010-01-29
US7807430B2 (en) 2010-10-05
PT1319064E (en) 2008-02-29

Similar Documents

Publication Publication Date Title
AU2001280812A1 (en) Gsk3 polypeptides
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
WO2004112701A3 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
BR9713186A (en) 1,3-diheterocyclic metalloprotease inhibitors
DE60330485D1 (en) FOR THE TREATMENT OF DIABETES
AU3986493A (en) Protease and related DNA compounds
ATE231496T1 (en) SACCHARINE DERIVATIVES AS PROTEOLYTIC ENZYMIN HIBITORS
WO2003009855A3 (en) Organo-phosphorous compounds for activating gamma/delta t cells
WO2003039454A3 (en) Beta-secretase inhibitors and methods of use
DE60025008D1 (en) DETERMINATION OF ADRENOMEDULLIN-BINDING PROTEINS
AU7934900A (en) Method of screening for inhibitors of asp2
WO2000034511A3 (en) Aβ-PEPTIDE SCREENING ASSAY
HUP9901751A3 (en) Novel substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
WO1998020034A3 (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses thereof
BR0112123A (en) Compound
ATE323505T1 (en) USE OF RECOMBINANT LUNG SURFACTANT FOR EARLY TREATMENT OF ACUTE LUNG DISEASE
DE69809785D1 (en) USE OF A RETINOIDIDE IN VIVO INCREASING THE UNCOVERING OF THE UCP2 PROTEIN
DE59609977D1 (en) TRAPIDIL FOR USE IN THE THERAPY OF IMMUNO-MODULATABLE INFLUENCES
BR9915572A (en) Process of treatment of sickle cell disease and thalassemia
WO2002058323A3 (en) Method for identifying modulators of bace
ATE391915T1 (en) USE OF GRF-1 PROTEIN TO SELECT MOLECULES
ATE180478T1 (en) USE OF SUBSTITUTED 6-AMINO-4H-PYRANES
ATE311901T1 (en) USE OF TGF-BETA INHIBITORS TO TREAT CEREBRAL DISEASES
WO2004047854A3 (en) Methods for the treatment of alzheimers disease and compositions therefore
DE60203726D1 (en) TOPICAL COMPOSITION CONTAINING BRUCIN AND ITS USE FOR THE TREATMENT OF SKIN DAMAGE